What is QuikClot®?
Innovation in hemostasis

QuikClot® hemostatic devices are different from standard surgical gauzes and other hemostatic agents. They stop bleeding significantly faster and are more effective than standard gauzes—and they are just as safe and intuitive to use.1-5

Unlike other hemostatics, QuikClot® devices are impregnated with kaolin, an inorganic mineral that accelerates the body’s natural clotting ability and produces no exothermic reaction.1,2 You or your team can achieve hemostasis confidently—without worry of instigating an allergic response.7,8


QuikClot® devices do not contain7:

  • Animal proteins
  • Human proteins
  • Shellfish
  • Botanicals

QuikClot® hemostatic devices for a range of uses

QuikClot® devices come in many different forms and sizes, which are adaptable to treat a broad range of bleeding situations. They are trusted and relied on by: 

QuikClot® hemostatic devices at a glance:

Fast & Effective
  • Promotes clotting within minutes of application1-5
  • The Committee on Tactical Combat Casualty Care (CoTCCC) recommends QuikClot Combat Gauze® as the hemostatic agent of choice for compressible hemorrhage not amenable to tourniquet use6
  • No shellfish, human, or animal proteins7
  • Low-to-no risk of adverse reactions8
  • Familiar and easy-to-use format
  • Conforms readily to wound site
Efficient & Valuable
  • Less expensive than protein-based products; may reduce the need for additional expensive treatments4
  • Stops bleeding faster than standard gauze1-5

View Products

QuikClot® kaolin technology accelerates the body’s natural clotting cascade2

For more than 5 years, QuikClot® hemostatic devices have been made with kaolin. Kaolin works on contact with blood to immediately initiate the clotting process by activating factor XII.2 This reaction leads to the transformation of factor XII, factor XI, and prekallikrein to their activated forms, which instigates the rest of the coagulation cascade.9


QuikClot® hemostatic devices promote clotting within minutes1-5

Trauma is a major cause of death and disability and the second most expensive healthcare problem in the United States. Approximately 40% of trauma-related deaths are due to bleeding or its consequences, establishing hemorrhage as the most common cause of preventable death in trauma.10

QuikClot® devices, applied with manual pressure, promote clotting within minutes from application to help you and your team save more lives.


QuikClot Combat Gauze® is recommended by CoTCCC for all 5 branches of the US military6

In 2008, after extensive testing, the CoTCCC chose QuikClot Combat Gauze® as the only hemostatic dressing used by all branches of the US military for compressible hemorrhage not amenable to tourniquet use or as an adjunct to tourniquet removal if evacuation time is anticipated to be longer than 2 hours.6 Today, QuikClot Combat Gauze® still remains the hemostatic device of choice by the CoTCCC. The Department of Defense is funding research to explore other applications of QuikClot® products in bleeding associated with traumatic injuries. QuikClot® dressings are credited with saving lives.


Read the test results published in the Journal of Trauma

QuikClot®: Our history of success

QuikClot® hemostatic devices deliver the kind of innovation you can expect from Z-Medica®.

  •  2002
    • Novel hemostatic agent discovered–original Generation 1 product developed
    • Z-Medica Corporation founded
  •  2002-present
    • US military begins using and continues to use QuikClot® products
  •  2005
    • Second-generation “bean bag” products ACS+ and 1st Response are introduced
  •  2006
    • Third-generation kaolin-based hemostatic agent is developed
  •  2008
    • QuikClot Combat Gauze® introduced
    • QuikClot Combat Gauze® becomes the only hemostatic dressing recommended by CoTCCC for US military use for compressible hemorrhage not amenable to tourniquet use or as an adjunct to tourniquet removal if evacuation time is anticipated to be longer than 2 hours6
  •  2009
    • QuikClot® InterventionalTM is released
  •  2013
    • Topical surgical wound/traumatic bleeding clearance granted by FDA
    • QuikClot® InterventionalTM cleared for drug-induced, anticoagulated patients 
  •  2014
    • CoTCCC reaffirms QuikClot Combat Gauze® as the hemostatic dressing of choice for compressible hemorrhage not amenable to tourniquet use 

Show TimelineHide Timeline

References: 1. Trabattoni D, Montorsi P, Fabbiocchi F, Lualdi A, Gatto P, Bartorelli A. A new kaolin-based haemostatic bandage compared with manual compression for bleeding control after percutaneous coronary procedures. Eur Radiol. 2011;21:1687-1691. 2. Politi L, Aprile A, Paganelli C, et al. Randomized clinical trial on short-time compression with kaolin-filled pad: a new strategy to avoid early bleeding and subacute radial artery occlusion after percutaneous coronary intervention. J Interven Cardiol. 2011;24:65-72. 3. Trabattoni D, Gatto P, Bartorelli A. A new kaolin-based hemostatic bandage use after coronary diagnostic and interventional procedures. Int J Cardiol. 2012;156(1):53-54. 4. Lamb KM, Pitcher HT, Cavarocchi NC, Hirose H. Vascular site hemostasis in percutaneous extracorporeal membrane oxygenation therapy. Open Cardiovasc Thorac Surg J. 2012;5:8-10. 5. Pahari M, Moliver R, Lo D, Pinkerton D, Basadonna G. QuikClot® Interventional™ Hemostatic Bandage (QCI): a novel hemostatic agent for vascular access. Cath Lab Digest. 2010;18(1):28-30. http://www.cathlabdigest.com/articles/QuikClot®-Interventional™-Hemostatic-Bandage-QCI-A-Novel-Hemostatic-Agent-Vascular-Access. Accessed on August 10, 2014. 6. Tactical Combat Casualty Care Guidelines 2014. http://www.itstactical.com/wp-content/uploads/2014/07/TCCC-Guidelines-update-june-2-2014.pdf. Accessed September 16, 2014. 7. QuikClot Material Safety Data Sheet (MSDS), http://www.unimedcorp.com/MSDS/MSDS_QuikClotCombatGauze.pdf. Updated August 14, 2008. Accessed September 12, 2014. 8. QuikClot lnterventional-A Hemostatic Bandage 510(k) Summary. US Food and Drug Administration. Updated March 11, 2013. http://www.accessdata.fda.gov/cdrh_docs/pdf12/k120782.pdf. Accessed September 12, 2014. 9. Ilesanmi OO. Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy. http://openi.nlm.nih.gov/detailedresult.php?img=3222266_hr-2010-1-e2-g008&req=4. Accessed September 13, 2014. 10. Curry N, Hopewell S, Dorée C, Hyde C, Brohi K, Stanworth S. The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit Care. 2011;15(2):R92. 11. Kheirabadi BS, Mace JE, Terrazas IB, et al. Safety evaluation of new hemostatic agents, smectite granules, and kaolin-covered gauze in a vascular injury wound model in swine. J Trauma. 2010;68:269-278. 12. Kheirabadi BS, Scherer MR, Estep JS, Dubick MA, Holcomb JB. Determination of efficacy of new hemostatic dressings in a model of extremity arterial hemorrhage in swine. J Trauma. 2009;67:450-460. 13. Kheirabadi BS. Evaluation of topical hemostatic agents for combat wound treatment. US Army Med Dep J. 2011;25-37.

Show ReferencesHide References


Our site includes links to third party sites in which the Z-Medica® Privacy Policy and Terms of Use do not apply. Please read the privacy policy for every third party website you visit.